Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DAPT Clear all
Not yet recruiting Not applicable Interventional

The TERUMO FRED X EARLY FEASIBILITY STUDY (FAST) STUDY.

NCT07761598
View directory record Official record
Conditions
Aneurysm Cerebral
Interventions
Fred X Medical Device Intervention for Aneurysm Treatment with DAPT Therapy.
Device
Lead sponsor
Jacobs institute
Other
Eligibility
22 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Not listed Phase 4 Interventional

Implementing Precision Medicine Approaches to Guide Anti-platelet Selection

NCT04090281
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

NCT06691191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 90 mg, Prasugrel 10 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 3 Interventional

One-Month DAPT in CABG Patients

NCT05997693
View directory record Official record
Conditions
Chronic Coronary Disease
Interventions
Ticagrelor 90 MG, Low-dose aspirin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Englewood, New Jersey • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 6, 2026, 9:54 AM EDT
Not listed Not applicable Interventional

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

NCT02594501
View directory record Official record
Conditions
Angina, Stable, Angina, Unstable, Anticoagulants
Interventions
COBRA PzF, Drug Eluting Stent
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
22
States / cities
Newark, Delaware • Jacksonville, Florida • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 6, 2026, 9:54 AM EDT
Completed Not applicable Interventional Results available

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

NCT01925794
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
COBRA PzF
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
22
States / cities
Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 6, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242
View directory record Official record
Conditions
Cardiovascular Disease, Interventional Cardiology
Interventions
Aspirin, Placebo, ticagrelor
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
9,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional

Vascular Trial Associated Registry Pilot

NCT07076082
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Clopidogrel (Plavix) Pharmacogenetic Test Reagents
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
45 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

NCT06821191
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
clopidogrel 75 mg, Prasugrel 5 mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 6, 2026, 9:54 AM EDT
Not listed No phase listed Observational

Comparison of the VerifyNow® Aspirin Test and PRUTest® Platelet Reactivity Tests With Investigational Reagent to Reagents Registered in Japan

NCT03615846
View directory record Official record
Conditions
Platelet Aggregation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Completed No phase listed Observational

Management of Antiplatelet Regimen During Surgical Procedures

NCT03981835
View directory record Official record
Conditions
Cardiac Surgery, Surgery, Percutaneous Coronary Intervention, Surgery--Complications
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Jacksonville, Florida • Dallas, Texas • Fredericksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Active, not recruiting Not applicable Interventional

SIMPLAAFY Clinical Trial

NCT06521463
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX Pro LAAC Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 6, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 6, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 6, 2026, 9:54 AM EDT
Completed Not applicable Interventional Results available

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

NCT03647475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Combination Product
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 6, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 6, 2026, 9:54 AM EDT